Myovant Sciences

77 articles with Myovant Sciences

• Myovant Sciences to Present at Upcoming December Investor Conferences

  11/23/2020

  Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences:

• Myovant Sciences Announces New Employment Grants Under NYSE Rule 303A.08

  11/17/2020

  Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards for 72 new employees with a grant date of November 15, 2020 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Company Manual Rule 303A.08.   The new employees received, in the aggregate, restricted stoc

• Myovant Sciences Announces Corporate Updates and Financial Results for Second Quarter Fiscal Year 2020

  11/12/2020

  FDA Priority Review of New Drug Application (NDA) for relugolix monotherapy tablet for advanced prostate cancer on track for decision by December 20, 2020 target action date

• Myovant Sciences to Host Second Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on November 12, 2020

  11/2/2020

  Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter 2020, ended September 30, 2020. The webcast and conference call will be held at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on November 12, 2020. Investors and the general public may access a live

• Myovant’s Relugolix Retains Strong Probability of FDA Approval Despite Equivalence for Castration Resistance-Free Survival

  10/30/2020

  Myovant is a healthcare company developing innovative treatments for women’s health and prostate cancer. Myovant is currently evaluating their lead gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix, in late-stage clinical programs for uterine fibroids, endometriosis, and prostate cancer.

• 

  Clinical Catch-Up: October 19-23

  10/26/2020

  It was another busy week for clinical trial updates and news. Here’s a look.
• 

  BioSpace Global Roundup, Oct. 22

  10/22/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and Uterine Fibroids

  10/21/2020

  Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the presentation of data from clinical studies of its once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis and in women with uterine fibroids

• Myovant Sciences Appoints Ryan Crowe as Vice President, Investor Relations

  10/14/2020

  Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Ryan Crowe as vice president, investor relations. In addition to managing day-to-day interactions with analysts and investors, Mr. Crowe will be responsible for developing and implementing a comprehensive and strategic global investor relations program. He will report to Frank Karbe, Myovant’s president an

• Myovant Sciences Presents Additional Data on Bone Mineral Density in Women with Uterine Fibroids from Phase 3 LIBERTY Program and from Prospective Observational Study

  9/14/2020

  Relugolix combination therapy maintained bone mineral density through one year, consistent with bone mineral density changes observed in untreated women Findings presented at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting Virtual Event

• Myovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids

  8/17/2020

  Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that its New Drug Application (NDA) for once-daily, oral relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of women with heavy menstrual bleeding associated with uterine fibroids has been accepted for review by

• Myovant Sciences Announces Corporate Updates and Financial Results for First Quarter Fiscal Year 2020

  8/11/2020

  New Drug Application (NDA) for relugolix monotherapy tablet in advanced prostate cancer accepted for Priority Review by the FDA with target action date of December 20, 2020 NDA for relugolix combination tablet in uterine fibroids submitted in May 2020 Additional USD 200 million low-interest, five-year term loan commitment from Sumitomo Dainippon Pharma and commercial collaboration agreement with Sunovion Pharmaceuticals increases financial flexibility and provides access to well-establis

• Myovant Sciences Announces Further Financing Support from Sumitomo Dainippon Pharma and Commercial Collaboration with Sunovion Pharmaceuticals

  8/5/2020

  USD 200 million low-interest, five-year term loan commitment from Sumitomo Dainippon Pharma to further support planned commercialization of relugolix across multiple indications Agreement with Sunovion Pharmaceuticals provides access to well-established commercial infrastructure currently utilized across multiple successful products BASEL, Switzerland, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men,

• Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Phase 3 LIBERTY Studies in Women with Uterine Fibroids and from Ovulation Inhibition Study

  7/6/2020

  Data from Phase 3 LIBERTY program show improvement in patient-reported outcomes in addition to improvement in hemoglobin levels in anemic women Detailed data from ovulation inhibition study demonstrate 100% ovulation inhibition and 100% return of ovulation upon treatment discontinuation Findings presented during European Society of Human Reproduction and Embryology (ESHRE) virtual 36th Annual Meeting taking place July 5-8, 2020

• 

  Clinical Catch-Up: June 22-26

  6/29/2020

  It was a busy week for clinical trial updates. Here’s a look.

• Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis

  6/23/2020

  Co-primary endpoints met with response rates of 74.5% for dysmenorrhea (menstrual pain) and 58.5% for non-menstrual pelvic pain (p-values < 0.0001) Women receiving relugolix combination therapy, on average, had a 73.3% reduction on the Numerical Rating Scale for dysmenorrhea from 7.3 (severe pain) to 1.8 (mild pain) Achieved all seven key secondary endpoints, including dyspareunia (painful intercourse) and a greater proportion of women not using opioids, with a generally well-tolerat

• 

  Myovant's Relugolix Combo Hits the Mark in Endometriosis, Heads to FDA for Prostate Cancer

  6/23/2020

  Relugolix is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist.

• Myovant Sciences Announces Priority Review and FDA Acceptance of New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer

  6/22/2020

  Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that its New Drug Application (NDA) for once-daily, oral relugolix (120 mg) for the treatment of men with advanced prostate cancer has been accepted for Priority Review by the U.S. Food and Drug Administration (FDA). 

• 

  Myovant’s Prostate Cancer Drug Relugolix Demonstrates Strong Data in Phase III

  6/1/2020

  The company presented the data at the American Society of Clinical Oncology Virtual Scientific Program and also published data simultaneously in the New England Journal of Medicine.

• Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids

  6/1/2020

  NDA is supported by positive data from two Phase 3 studies and a long-term extension study, demonstrating sustained reduction in heavy menstrual bleeding while maintaining bone health through one year If approved, relugolix combination tablet would be the first once-daily, oral treatment for women with heavy menstrual bleeding associated with uterine fibroids in the U.S.   BASEL, Switzerland, June 01, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on